Palatin Technologies (NYSE:PTN) Coverage Initiated at assumed coverage on shares of Palatin Technologies (NYSE:PTNGet Rating) in a report issued on Sunday. The brokerage set a “sell” rating on the stock.

Shares of Palatin Technologies stock opened at $0.36 on Friday. The firm has a market cap of $84.45 million, a PE ratio of -2.28 and a beta of 0.99. The business’s 50 day moving average is $0.40. Palatin Technologies has a 1-year low of $0.32 and a 1-year high of $0.96. The company has a current ratio of 3.53, a quick ratio of 3.63 and a debt-to-equity ratio of 0.01.

About Palatin Technologies (Get Rating)

Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.

Featured Stories

Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with's FREE daily email newsletter.